LUPIN vs NEULANDLAB: Stock Comparison

Lupin Limited vs Neuland Laboratories Limited

Live data: 24 July 2026, 4:08 PM IST • Source: NSE and company filings

Lupin Limited is the larger company by market capitalisation. Lupin Limited shows a lower P/E, a higher ROE and a higher dividend yield, while Neuland Laboratories Limited shows faster revenue growth, lower leverage and a higher net margin. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Lupin Limited and Neuland Laboratories Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, LUPIN is more favourable on 6 of 13 scored metrics and NEULANDLAB on 7These counts are context-free and are not an overall rating.

Key Differences

Market Cap
LUPIN is the larger company
₹1.08 L Cr vs ₹23,730 Cr
P/E Ratio
LUPIN has a lower P/E
20.35x vs 65.46x
P/B Ratio
LUPIN has a lower P/B
4.83x vs 12.71x
EPS
NEULANDLAB has higher earnings per share
₹293.13 vs ₹116.56
Dividend Yield
LUPIN has a higher dividend yield
0.48% vs 0.06%
Revenue Growth (TTM YoY)
NEULANDLAB has faster revenue growth
136.4% vs 31.9%
EPS Growth (TTM YoY)
NEULANDLAB has faster EPS growth
664.4% vs 89%
Qtr Sales Growth
NEULANDLAB has stronger quarterly sales growth
136% vs 31.9%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricLUPINNEULANDLAB
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricLUPINNEULANDLAB
Live Price₹2,370.5₹18,546
Day Change-1.08%0.62%
Volume7.26 L11,320
52-Week High₹2,529.5₹20,089
52-Week Low₹1,836.8₹11,500
Distance from 52W High-6.29%-7.68%

Valuation

MetricLUPINNEULANDLAB
Market Cap₹1.08 L Cr₹23,730 Cr
P/E Ratio20.35x65.46x
P/B Ratio4.83x12.71x
EPS₹116.56₹293.13
Book Value₹491.29₹1,460.02
Dividend Yield0.48%0.06%

Growth

MetricLUPINNEULANDLAB
Revenue Growth (TTM YoY)31.9%136.4%
EPS Growth (TTM YoY)89%664.4%
Qtr Sales Growth31.9%136%
Qtr Profit Growth101%665%

Profitability & Leverage

MetricLUPINNEULANDLAB
ROE29.1%21.4%
ROCE30.3%26.6%
Net Margin17.65%17.99%
Operating Margin31.5%28.4%
Debt to Equity0.29x0.16x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricLUPINNEULANDLAB
Promoter Holding46.57%32.62% 0.01 pp
FII Holding22.42% 0.71 pp21.08% 0.62 pp
DII Holding24.65% 0.67 pp16.51% 0.67 pp
Public Holding6.08% 0.03 pp29.79% 1.28 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Lupin Limited and Neuland Laboratories Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.